{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Type+2+Diabetes+With+Chronic+Kidney+Disease&page=2", "query": { "condition": "Type 2 Diabetes With Chronic Kidney Disease", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Type+2+Diabetes+With+Chronic+Kidney+Disease&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-07-24T22:26:00.645Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01200394", "title": "A Phase 2, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of PF-00489791 In Patients With Type 2 Diabetes And Overt Nephropathy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diabetic Nephropathies" ], "interventions": [ { "name": "PF-00489791", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 256, "start_date": "2010-12", "completion_date": "2013-08", "has_results": true, "last_update_posted_date": "2019-03-12", "last_synced_at": "2026-07-24T22:26:00.645Z", "location_count": 63, "location_summary": "Huntsville, Alabama • Glendale, Arizona • Tempe, Arizona + 46 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Tempe", "state": "Arizona" }, { "city": "Tempe", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01200394" }, { "nct_id": "NCT04990427", "title": "CLBS201 in Patients with Chronic Kidney Disease (CKD) and Type 2 Diabetes Mellitus (T2DM)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Kidney Diseases" ], "interventions": [ { "name": "CLBS201", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Lisata Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 6, "start_date": "2022-01-10", "completion_date": "2023-01-26", "has_results": false, "last_update_posted_date": "2024-10-09", "last_synced_at": "2026-07-24T22:26:00.645Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04990427" }, { "nct_id": "NCT06717698", "title": "A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Kidney Disease" ], "interventions": [ { "name": "NNC0519-0130", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Semaglutide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novo Nordisk A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 465, "start_date": "2024-12-02", "completion_date": "2026-09-17", "has_results": false, "last_update_posted_date": "2026-03-11", "last_synced_at": "2026-07-24T22:26:00.645Z", "location_count": 18, "location_summary": "San Dimas, California • San Ramon, California • Aurora, Colorado + 14 more", "locations": [ { "city": "San Dimas", "state": "California" }, { "city": "San Ramon", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Fleming Island", "state": "Florida" }, { "city": "Hollywood", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06717698" }, { "nct_id": "NCT04960514", "title": "Prospective Decision Impact Trial of KidneyIntelX", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Diabetic Kidney Disease", "Chronic Kidney Disease Stage 1", "Chronic Kidney Disease Stage 2", "Chronic Kidney Disease, Stage 3 (Moderate)" ], "interventions": [ { "name": "KidneyIntelX", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DIAGNOSTIC_TEST" ], "sponsor": "Renalytix AI, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "23 Years", "maximum_age": null, "sex": "ALL", "summary": "23 Years and older" }, "enrollment_count": 2000, "start_date": "2021-11-22", "completion_date": "2026-12-01", "has_results": false, "last_update_posted_date": "2024-04-12", "last_synced_at": "2026-07-24T22:26:00.645Z", "location_count": 1, "location_summary": "Winston-Salem, North Carolina", "locations": [ { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT04960514" }, { "nct_id": "NCT00920764", "title": "A Study of Atrasentan on Reducing Albuminuria in Type 2 Diabetic Nephropathy Treated With Renin-Angiotensin System Inhibitors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Kidney Disease", "Diabetic Nephropathy" ], "interventions": [ { "name": "Placebo for Atrasentan 0.2 mg/mL solution", "type": "DRUG" }, { "name": "0.25 mg Atrasentan QD", "type": "DRUG" }, { "name": "0.75 mg Atrasentan QD", "type": "DRUG" }, { "name": "1.75 mg Atrasentan QD", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie (prior sponsor, Abbott)", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 92, "start_date": "2009-06", "completion_date": "2010-05", "has_results": false, "last_update_posted_date": "2018-06-06", "last_synced_at": "2026-07-24T22:26:00.645Z", "location_count": 24, "location_summary": "Tempe, Arizona • Azusa, California • Los Angeles, California + 16 more", "locations": [ { "city": "Tempe", "state": "Arizona" }, { "city": "Azusa", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00920764" }, { "nct_id": "NCT05570305", "title": "Zibotentan and Dapagliflozin in Patients With Type 2 Diabetes and Elevated Albuminuria", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Kidney Diseases" ], "interventions": [ { "name": "Zibotentan", "type": "DRUG" }, { "name": "Dapagliflozin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Dapagliflozin and Zibotentan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University Medical Center Groningen", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 42, "start_date": "2022-10-06", "completion_date": "2025-03-05", "has_results": false, "last_update_posted_date": "2025-04-30", "last_synced_at": "2026-07-24T22:26:00.645Z", "location_count": 1, "location_summary": "Aurora, Colorado", "locations": [ { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT05570305" }, { "nct_id": "NCT06461273", "title": "Food is Medicine vs Lifestyle Medicine For Cardiovascular Kidney Metabolic (CKM) Syndrome", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Diabetes Mellitus", "Metabolic Syndrome", "Obesity", "Hypertension,Essential", "Hyperlipidemias", "Cardiovascular Diseases", "Kidney Disease, Chronic" ], "interventions": [ { "name": "Lifestyle Medicine Program", "type": "BEHAVIORAL" }, { "name": "Medically Tailored Groceries", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Rutgers, The State University of New Jersey", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 37, "start_date": "2024-10-12", "completion_date": "2025-04-11", "has_results": false, "last_update_posted_date": "2026-07-09", "last_synced_at": "2026-07-24T22:26:00.645Z", "location_count": 1, "location_summary": "Newark, New Jersey", "locations": [ { "city": "Newark", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT06461273" }, { "nct_id": "NCT01487109", "title": "A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-499 in Type 2 Diabetic Nephropathy Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Type 2 Diabetes Mellitus", "Chronic Kidney Disease" ], "interventions": [ { "name": "CTP-499", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Concert Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 170, "start_date": "2012-01", "completion_date": "2015-01", "has_results": false, "last_update_posted_date": "2021-08-16", "last_synced_at": "2026-07-24T22:26:00.645Z", "location_count": 49, "location_summary": "Tempe, Arizona • Harrisburg, Arkansas • Little Rock, Arkansas + 38 more", "locations": [ { "city": "Tempe", "state": "Arizona" }, { "city": "Harrisburg", "state": "Arkansas" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Burbank", "state": "California" }, { "city": "Chula Vista", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01487109" }, { "nct_id": "NCT01464320", "title": "A Study to Evaluate the Safety and Tolerability of ABT-614 and Its Effect on Kidney Function in Subjects With Type 2 Diabetes and Chronic Kidney Disease With Protein in Their Urine.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Type 2 Diabetics, Chronic Kidney Disease, Protein in Urine" ], "interventions": [ { "name": "ABT-614", "type": "DRUG" }, { "name": "Placebo Comparator", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Abbott", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "19 Years to 70 Years" }, "enrollment_count": 16, "start_date": "2011-11", "completion_date": "2012-04", "has_results": false, "last_update_posted_date": "2012-08-22", "last_synced_at": "2026-07-24T22:26:00.645Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01464320" }, { "nct_id": "NCT06297603", "title": "Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Type 2 Diabetes" ], "interventions": [ { "name": "Retatrutide", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 320, "start_date": "2024-03-15", "completion_date": "2026-11", "has_results": false, "last_update_posted_date": "2026-07-20", "last_synced_at": "2026-07-24T22:26:00.645Z", "location_count": 28, "location_summary": "Huntsville, Alabama • Sun City West, Arizona • Apple Valley, California + 24 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Sun City West", "state": "Arizona" }, { "city": "Apple Valley", "state": "California" }, { "city": "Canoga Park", "state": "California" }, { "city": "Escondido", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06297603" } ] }